Mitsubishi UFJ Asset Management Co. Ltd. Buys 9,578 Shares of Insulet Corporation $PODD

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Insulet Corporation (NASDAQ:PODD) by 7.7% during the second quarter, HoldingsChannel.com reports. The firm owned 134,357 shares of the medical instruments supplier’s stock after buying an additional 9,578 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Insulet were worth $42,212,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. American Century Companies Inc. lifted its holdings in shares of Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after buying an additional 297,734 shares in the last quarter. Nuveen LLC bought a new stake in Insulet during the 1st quarter worth approximately $74,163,000. Kayne Anderson Rudnick Investment Management LLC lifted its stake in Insulet by 1,316.5% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock worth $50,818,000 after purchasing an additional 179,850 shares in the last quarter. Vanguard Group Inc. lifted its stake in Insulet by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after purchasing an additional 178,976 shares in the last quarter. Finally, AustralianSuper Pty Ltd boosted its holdings in Insulet by 487.5% in the 2nd quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier’s stock valued at $64,460,000 after purchasing an additional 170,247 shares during the period.

Insider Activity at Insulet

In related news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

PODD has been the topic of several research analyst reports. UBS Group upped their price target on shares of Insulet from $320.00 to $355.00 and gave the stock a “neutral” rating in a report on Friday. BTIG Research reiterated a “buy” rating and set a $370.00 price target on shares of Insulet in a research report on Thursday. Oppenheimer raised their target price on shares of Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research note on Monday, September 8th. Raymond James Financial raised their price objective on shares of Insulet from $360.00 to $366.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Jefferies Financial Group increased their target price on Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average target price of $374.10.

Insulet Stock Performance

Insulet stock opened at $320.35 on Tuesday. The firm has a fifty day simple moving average of $324.67 and a two-hundred day simple moving average of $310.73. Insulet Corporation has a twelve month low of $230.05 and a twelve month high of $353.50. The company has a market capitalization of $22.55 billion, a PE ratio of 97.37, a P/E/G ratio of 2.64 and a beta of 1.39. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company’s quarterly revenue was up 29.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.